Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
25.75    0.00 (0.00%)
Bid:
25.50
Ask:
26.00
Spread: 0.50 (1.961%)
Market Cap: £129.66m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Director/PDMR Dealings

28 Jul 2023 07:00

RNS Number : 4838H
Duke Royalty Limited
28 July 2023
 

28 July 2023

 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Performance Share Awards ("PSAs")

Issue of Equity

Director/PDMR Dealings

 

New grant under LTIP

 

 

Duke Royalty Limited (AIM: DUKE), a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, announces that the Company's Remuneration Committee has approved the grant of a total of 3,662,900 conditional rights to acquire ordinary shares of no par value (PSAs) under the Company's Long-Term Incentive Plan ("LTIP"). The LTIP framework was detailed within the Company's Admission Document which was published on 20 March 2017 and was put into place post Admission.

 

PSAs for the financial year to 31 March 2023 have been granted are as follows:

 

Neil Johnson

847,100

Charlie Cannon Brookes

762,400

Other employees (non-PDMRs)

2,053,400

Total

3,662,900

 

The PSAs vest after a period of three years and are subject to various performance conditions outlined in the Company's admission document (and available on the Company's website) and set by the Remuneration Committee, all in accordance with the LTIP rules. The PSAs will be subject to performance conditions, (50 per cent. based on growth in total shareholder return ("TSR") and 50 per cent. on growth in total cash available for distribution per share ("TCAD per Share")). TSR can be defined as the returns generated by shareholders based on the combined value of the dividends paid out by the Company and the share price performance over the period in question.

 

Vesting of 2020 PSAs, transfer from EBT & Director/PDMR interests

 

The Company also announces that a total of 7,665,000 PSAs, previously granted under the Company's LTIP in relation to the financial year ended 31 March 2020, have vested, representing 100% of the PSAs granted at that time.

 

Following the various transactions detailed above, the following Directors / PDMRs have the following total interest in ordinary shares:

 

 

Director/PDMR

Total ordinary shares held

Neil Johnson (1)

7,129,173

Charlie Cannon Brookes (2)

10,000,000

 

 

(1) Mr Johnson is Abingdon Capital Corporation's sole voting shareholder which legally owns 2,123,149 ordinary shares included within this figure.

 

(2) Mr Cannon Brookes a Director and shareholder of Arlington Asset Management Limited ("Arlington"). This figure includes 4,000,000 ordinary shares legally owned by Arlington.

 

 

Total voting rights and EBT shares

 

In order to maintain an appropriate level of headroom within the Company's EBT, the Company has issued 3,954,700 new ordinary shares into the Duke Royalty Employee Benefit Trust ("EBT"), ownership of which shall be transferred, in part or in full, to individual beneficiaries, subject to achievement of the performance criteria following the vesting period. Application has been made for these 3,954,700 shares to be admitted to trading on AIM, which is expected to occur on 31 July 2022 ("Admission"). 

 

Following Admission and transfer of the 3,954,700 shares to LTIP beneficiaries, the Company will have 421,488,734 ordinary shares in issue admitted to trading on AIM, of which 6,062,700 will be held by the EBT. This figure (421,488,734) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to, their interest in the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

For further information, please contact www.dukeroyalty.com, or contact: 

 

Duke Royalty Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 231 816

Cenkos Securities plc 

(Nominated Adviser

and Joint Broker)

 

Stephen Keys / Callum Davidson / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell / Alice Cho / Matthew Elliott

+44 (0) 20 3757 6882 dukeroyalty@secnewgate.co.uk

 

 

 

 

Notifications of dealings by PDMRs:

 

1.

Details of the person discharging managerial responsibilities/persons closely associated

a)

Name

Neil Johnson

2.

Reason for notification

a)

Position/Status

Chief Executive Officer

b)

Initial notification/amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Duke Royalty Limited

b)

LEI

213800GUTKPSJ39SER44

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary shares of nil par value

GG00BYZSSY63

b)

Nature of transaction

Grant of conditional performance share awards under LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

847,100

d)

Aggregated Information

n/a

e)

Date of transaction

Award date: 27 July 2023

f)

Place of transaction

Outside a trading venue

 

1.

Details of the person discharging managerial responsibilities/persons closely associated

a)

Name

Neil Johnson

2.

Reason for notification

a)

Position/Status

Chief Executive Officer

b)

Initial notification/amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Duke Royalty Limited

b)

LEI

213800GUTKPSJ39SER44

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary shares of nil par value

GG00BYZSSY63

b)

Nature of transaction

Acquisition of ordinary shares following vesting of conditional performance share awards under LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

1,500,000

d)

Aggregated Information

n/a

e)

Date of transaction

27 July 2023

f)

Place of transaction

Outside a trading venue

 

1.

Details of the person discharging managerial responsibilities/persons closely associated

a)

Name

Charlie Cannon Brookes

2.

Reason for notification

a)

Position/Status

Executive Director

b)

Initial notification/amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Duke Royalty Limited

b)

LEI

213800GUTKPSJ39SER44

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary shares of nil par value

GG00BYZSSY63

b)

Nature of transaction

Grant of conditional performance share awards under LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

762,400

d)

Aggregated Information

n/a

e)

Date of transaction

Award date: 27 July 2023

f)

Place of transaction

Outside a trading venue

1.

Details of the person discharging managerial responsibilities/persons closely associated

a)

Name

Charlie Cannon Brookes

2.

Reason for notification

a)

Position/Status

Executive Director

b)

Initial notification/amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Duke Royalty Limited

b)

LEI

213800GUTKPSJ39SER44

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary shares of nil par value

GG00BYZSSY63

b)

Nature of transaction

Acquisition of ordinary shares following vesting of conditional performance share awards under LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

1,450,000

d)

Aggregated Information

n/a

e)

Date of transaction

27 July 2023

f)

Place of transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHNKOBPFBKDFOB
Date   Source Headline
28th May 20267:00 amRNSNotice of Results & Investor Presentation
31st Mar 20267:00 amRNSTrading and Operational Update
19th Mar 20267:00 amRNSInterim Dividend and Dividend Declaration
26th Jan 20267:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
18th Dec 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Dec 20257:00 amRNSInterim Financial Results
17th Oct 20257:00 amRNSFollow-On Investment into Step Investments Limited
1st Oct 20257:00 amRNSFollow-On Investment into Integrum Group Holdings
29th Sep 20257:00 amRNSTrading Update
18th Sep 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Aug 202511:17 amRNSResult of Annual General Meeting
1st Aug 20258:08 amRNSDirector/PDMR Dealings
11th Jul 20257:00 amRNSAnnual Report & Notice of Annual General Meeting
25th Jun 20257:00 amRNSFinal Results for the year ended 31 March 2025
19th Jun 20257:00 amRNSInterim Dividend and Dividend Declaration
2nd Jun 20257:00 amRNSFollow-On Investment into Existing Capital Partner
27th May 20257:00 amRNSNotice of Results & Investor Presentation
2nd Apr 20257:00 amRNSFollow-On Investment into Existing Capital Partner
31st Mar 20257:00 amRNSTrading and Operational Update
20th Mar 20257:00 amRNSInterim Dividend and Dividend Declaration
19th Feb 20257:00 amRNSFollow-On Investment into BPVA (Ireland) Limited
30th Dec 20247:00 amRNSTrading and Operational Update
17th Dec 202412:50 pmRNSInterim Dividend and Dividend Declaration
16th Dec 20247:00 amRNSInterim Results for the six months ended 30 Sep 24
4th Dec 20249:40 amRNSDirector/PDMR Shareholding
3rd Dec 202411:34 amRNSResult of General Meeting and Issue of Equity
22nd Nov 20243:38 pmRNSResult of Retail Offer and Broker Option
15th Nov 20247:00 amRNSResult of Placing
14th Nov 20245:02 pmRNSRetail Offer to raise up to £3.0 million
14th Nov 20245:01 pmRNSIssue of Equity
30th Sep 20247:00 amRNSTrading and Operational Update
19th Sep 20247:00 amRNSInterim Dividend and Dividend Declaration
3rd Sep 20247:00 amRNSFollow-On Investment into United Glass Group
1st Aug 20243:16 pmRNSDirector/PDMR Dealings
1st Aug 202411:40 amRNSResult of Annual General Meeting
22nd Jul 20247:00 amRNSFollow-On Investment into Step Investments Limited
15th Jul 20247:00 amRNSAnnual Report & Notice of Annual General Meeting
27th Jun 20247:00 amRNSFinal Results for the year ended 31 March 2024
20th Jun 202411:50 amRNSInterim Dividend and Dividend Declaration
3rd Jun 20247:00 amRNSNotice of Results
17th May 202411:45 amEQSHardman & Co Q&A on Duke Capital (DUKE) | Generating investor returns by uniquely meeting customer needs
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.